心脏神经支配显像作为器械治疗候选者风险分层工具的展望
本文评述123I-mIBG心脏神经支配显像的应用进展,指出ADMIRE-HF试验已证实去神经心肌与心脏事件的关联,并讨论将其扩展至指导ICD候选者筛选的潜力,认为此类研究可能为临床广泛采用奠定基础。
要点
- 123I-mIBG已获FDA批准用于评估心脏神经完整性。
- ADMIRE-HF试验主要证实123I-mIBG评估的去神经心肌与心脏事件相关。
- 本期JNC文章描述用123I-mIBG识别因心律失常低风险而最可能不受益于ICD的心肌病患者。
核心结论
- 心脏神经支配显像除风险分层外,应扩展至指导心脏科医生选择特定治疗干预的合适候选者。
研究设计与样本
- 本文为对本期Journal of Nuclear Cardiology所刊研究的评述性文章,非原创研究。
主要发现
- ADMIRE-HF前瞻性试验主要证实123I-mIBG评估的去神经心肌与心脏事件相关。
- 本期所评研究描述用123I-mIBG识别因心律失常低风险而最可能不受益于ICD的心肌病患者。
临床怎么用
- 123I-mIBG已获FDA批准用于评估心脏神经完整性。
- 心肌神经功能分子显像可扩展至指导特定治疗干预的候选者选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As a scintigraphic approach evaluating cardiac nerve integrity, 123I-metaiodobenzylguanidine (123I-mIBG) has been recently Food and Drug Administration approved. A great deal of progress has been made by the prospective ADMIRE-HF trial, which primarily demonstrated the association of denervated myocardium assessed by 123I-mIBG and cardiac events. However, apart from risk stratification, myocardial nerve function evaluated by molecular imaging should also be expanded to other clinical contexts, in particular to guide the referring cardiologist in selecting appropriate candidates for specific therapeutic interventions. In the present issue of the Journal of Nuclear Cardiology®, the use of 123I-mIBG for identifying cardiomyopathy patients, which would most likely not benefit from ICD due to low risk of arrhythmias, is described. If we aim to deliver on the promise of cardiac innervation imaging as a powerful tool for risk stratification in a manner similar to nuclear oncology, studies such as the one reviewed here may imply an important step to lay the proper groundwork for a more widespread adoption in clinical practice.
引用
- Werner RA. Cardiac innervation imaging as a risk stratification tool for potential device therapy candidates. J Nucl Cardiol. 2018. PMID: 30357580. doi:10.1007/s12350-018-01475-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。